Brief: Takeda Pharmaceutical - Currently Assessing Amount Of Provision To Be Recognized In Group Earnings For FY Ended March 31

Takeda Pharmaceutical

19/05/2026 02:27

May 19 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T:

TAKEDA PROVIDES AN UPDATE REGARDING JURY VERDICT IN AMITIZA ANTITRUST LITIGATION IN U.S. AND RELATED REVISION TO FY2025 FINANCIAL RESULTS

CURRENTLY ASSESSING AMOUNT OF PROVISION TO BE RECOGNIZED IN GROUP EARNINGS FOR FY ENDED MARCH 31, 2026

ONCE AMOUNT IS DETERMINED, WILL RECORD PROVISION AND REVISE FY2025/26 FINANCIAL STATEMENTS WITH TSE

DO NOT EXPECT FY2026 FINANCIAL FORECAST TO BE MATERIALLY IMPACTED EXCEPT FOR ADJUSTED FREE CASH FLOW FORECAST, DEPENDING ON AMOUNT AND TIMING OF ANY PAYMENT

Source text: ID:nTSqs83ead

Further company coverage: 4502.T